Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

JQ1 (+/-)

Inh 1268524-69-1 (6R,S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid 1,1-dimethylethyl ester
N° du produit ABIN7233265
  • Application
    Inhibition (Inh)
    Fonction
    Bromodomain inhibitor
    Attributs du produit
    JQ1 is a potent BET bromodomain inhibitor. IC50 = 17.7, 32.6, 76.9 and 12942 nM respectively for BRD2 (N-terminal (N)), BRD4 (C-terminal (C)), BRD4 (N) and CREBBP respectively. Competitive binding by JQ1 displaces the BRD4 fusion oncoprotein from chromatin, prompting squamous differentiation and specific antiproliferative effects in BRD4-dependent cell lines and patient-derived xenograft models establishing proof-of-concept for targeting protein-protein interactions of epigenetic readers.
    Pureté
    >98 %
    Chemical Name
    (6R,S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid 1,1-dimethylethyl ester
    Formula
    C23H25ClN4O2S
    Solubility
    Soluble in DMSO (up to 9 mg/ml) or in Ethanol (up to 9 mg/ml) with warming.
  • Restrictions
    For Research Use only
  • Format
    Powder
    Précaution d'utilisation
    GHS – Classification
    Pharmacologically active compound that has not been fully tested
    May be harmful if swallowed, inhaled or absorbed through skin
    Exposure may cause irritation to skin, eyes and upper respiratory tract
    Specific target organ toxicity - unknown
    Stock
    RT
  • Sujet
    Epigenetics,Proliferation,Bromodomain,Cancer,Posttranslational modification,Chromatin
    Poids moléculaire
    457.00
    Numéro CAS
    1268524-69-1
Vous êtes ici:
Support technique